Ascentage Pharma Group International (HK:6855)
:6855
Apg-3288
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (Cll/Sll, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (Mcl), Relapsed/Refractory Waldenström Macroglobulinemia (Wm), Relapsed/Refractory Marginal Zone Lymphoma (Mzl), Relapsed/Refractory Follicular Lymphoma (Fl)
Phase I
Not Yet Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Feb 01, 2026
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ascentage Pharma Group International (6855) have in its pipeline
6855 is currently developing the following drugs: Apg-3288, Olverembatinib 20Mg, Pld, Apg -2449. These drug candidates are in various stages of clinical development as the company works toward FDA approval.